Báo cáo khoa học: "Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size" ppsx

... 88:351-358. doi:10.1186/1748-717X-5-81 Cite this article as: Baba et al.: Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiation Oncology ... Araki N, Yano S, HIraoka M: Clinical outcomes of a phase I/ II study of 48 Gy of stereotactic body radiotherap...

Ngày tải lên: 09/08/2014, 09:20

... American experience with stereotactic body radiation therapy in non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung ... clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/ II non-small- cell lung cancer. International Journal of R...

Ngày tải lên: 09/08/2014, 09:20

... (40.3) Stage at initial diagnosis ypStage 0 3 (4.2) pStage I/ ypStage I 5 (7.0)/1 (1.4) pStage II/ypStage II 14 (19.7)/3 (4.2) pStage III/ypStage III 21 (29.6)/8 (11.3) pStage IV/ypStage IV 6 (8.5)/1 ... 1.8 Gy/fraction in 60 patients, 2.4 Gy/fraction in four patients, 2.7 Gy/fraction in one patient, 2.8 Gy/frac- tion in one patient, and a 3 Gy/fract ion in one patient. The radiation dos...

Ngày tải lên: 09/08/2014, 09:20

... still are feasible in terms of e.g. radiation dose escalation or alterations in concurrent therapy. ThebenefitsofANNscomparedtoconventional regression statistics comprise the capability of being more ... 0.001). Conclusions: We have in a preclinical investigation showed that the combination of early changes in several functional MRI parameters provides additional information about thera...

Ngày tải lên: 09/08/2014, 09:20

... 2011 Published: 28 March 2011 Reference 1. Li Feng, Liu Yongmei, Chen Huijiao, Liao Dianying, Shen Yali, Xu Feng, Wang Jin: EGFR and COX-2 protein expression in non-small cell lung cancer and ... Author details 1 Radiation Oncology, Tumor Center, West China Hospital, Sichuan University, PR China. 2 Department of Pathology, West China Hospital, Sichuan University, PR China. Receive...

Ngày tải lên: 10/08/2014, 10:21

... Daniele L, Macri L, Schena M, et al. Predicting gefitinib respon- siveness in lung cancer by fluorescence in situ hybridiza- tion/chromogenic in situ hybridization analysis of EGFR and HER2 in ... direct and valuable guidance for clinicians to make decision on EGFR-TKIs therapy. Key words: non-small cell lung cancer, EGFR, somatic mutation, tyrosine kinase inhibitor, gene...

Ngày tải lên: 08/08/2014, 17:20

... advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune ... of 80 Stage III Con:12 of 40 Con:17 of 40 Exp:1 6of 44 Exp:20 of 44 [23] ATV-NDV Stage I- IV Con:16 of 25 NO 7 C Exp:1 2of 25 [24] 17-1 Stage III Con:48 of 76 Co...

Ngày tải lên: 18/06/2014, 19:20

... zero-time serum concentration intercepts of biphasic i. v. and p.o. disposition curves; α, hybrid rate constants of the slope of distribution; β, hybri d rate constants of the slope of elimination; ... bacteria [5,11]. Norfloxacin is one of the first modern fluo- roquinolone antimicrobial agents featuring a fluorine atom in position 6 and a piperazinyl or pyrrolidinyl subst...

Ngày tải lên: 07/08/2014, 20:23

... CRP. Interleukin-6 (IL-6) is a multi-poietic cytokine that induces the growth and differentiation of immune cells, the production and expression of other cytokines, and acute-phase protein synthesis. ... correlates with the prognosis of patients with breast cancer. As IL-6 has a direct correlation with the stage of the disease it may indirectly correlate with the prognosis of the...

Ngày tải lên: 09/08/2014, 01:24